Regenerative Medicine Advanced Therapy Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
INAB | F | IN8bio, Inc. | -0.19 | |
PROK | D | ProKidney Corp. | 1.82 | |
HUMA | B | Humacyte, Inc. | 2.95 | |
LCTX | C | Lineage Cell Therapeutics, Inc. | 22.64 |
Related Industries: Biotechnology
Related ETFs - A few ETFs which own one or more of the above listed Regenerative Medicine Advanced Therapy stocks.
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
CBSE | A | Changebridge Capital Sustainable Equity ETF | 3.34 | |
CBLS | A | Changebridge Capital Long/Short Equity ETF | 2.54 | |
BTEC | C | Principal Healthcare Innovators Index ETF | 0.15 | |
IWC | C | iShares Microcap ETF | 0.1 | |
IBBQ | C | Invesco Nasdaq Biotechnology ETF | 0.05 |
Compare ETFs
Related Industries:
Biotechnology
- Regenerative Medicine Advanced Therapy
Regenerative Medicine Advanced Therapy (RMAT) is a designation given by the Food and Drug Administration to drug candidates intended to treat serious or life-threatening conditions under the 21st Century Cures Act. A RMAT designation allows for accelerated approval based surrogate or intermediate endpoints.RMAT goes beyond breakthrough therapy features by allowing for accelerated approval of drugs based on surrogate endpoints. A surrogate endpoint is a biomarker that substitutes for a direct endpoint, such as clinical benefit.
Popular Now
Recent Comments
- TraderMike on IZM
- SuccessfulGerbil321 on IZM
- TraderMike on IZM
- TraderMike on Today's Outage
- Crunching_The_Market on Today's Outage
From the Blog
Featured Articles